Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Wild-type PCSK9 inhibits LDL clearance but does not affect apoB-containing lipoprotein production in mouse and cultured cells.

Journal of lipid research - 1 Jun 2005

Lalanne Florent, Lambert Gilles, Amar Marcelo J A, Chétiveaux Maud, Zaïr Yassine, Jarnoux Anne-Laure, Ouguerram Khadija, Friburg José, Seidah Nabil G, Brewer H Bryan, Krempf Michel, Costet Philippe

Abstract excerpt

Mutations in Proprotein Convertase Subtilisin Kexin 9 (PCSK9) have been associated with autosomal dominant hypercholesterolemia. In vivo kinetic studies indicate that LDL catabolism was impaired and apolipoprotein B (apoB)-containing lipoprotein synthesis was enhanced in two patients presenting with the S127R mutation on PCSK9. To understand the physiological role of PCSK9, we overexpressed human PCSK9 in mouse...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenoviridae
Share to Apolipoproteins B

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Lipase

Share to Lipid Metabolism

Share to Lipoproteins, LDL

Share to Proprotein Convertase 9

Share to Proprotein Convertases

Share to Serine Endopeptidases

Source

Identifiers

PMID: 15741654
DOI: 10.1194/jlr.M400396-JLR200

Genes

PCSK9

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Wild-type PCSK9 inhibits LDL clearance but does not affect apoB-containing lipoprotein production in mouse and cultured cells.PMID 15741654Read ↗

The biology of PCSK9 from the endoplasmic reticulum to lysosomes: new and emerging therapeutics to control low-density lipoprotein cholesterol.Semantic proximity Read ↗

New Loss-of-Function Mutations in PCSK9 Reduce Plasma LDL Cholesterol.Semantic proximity Read ↗

PCSK9: a key modulator of cardiovascular health.Semantic proximity Read ↗

Functional impact of PCSK9 variants on LDL uptake in a knockout hepatic modelSemantic proximity Read ↗

PCSK9 Dominant Negative Mutant Results in Increased LDL Catabolic Rate and Familial HypobetalipoproteinemiaSemantic proximity Read ↗

Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and in livers of parabiotic mice.Semantic proximity Read ↗

Novel loss-of-function PCSK9 variant is associated with low plasma LDL cholesterol in a French-Canadian family and with impaired processing and secretion in cell culture.Semantic proximity Read ↗

The cellular trafficking of the secretory proprotein convertase PCSK9 and its dependence on the LDLR.Semantic proximity Read ↗

PCSK9 and LDL cholesterol: unravelling the target to design the bullet.Semantic proximity Read ↗

Beyond cholesterol metabolism: The pleiotropic effects of proprotein convertase subtilisin/kexin type 9 (PCSK9). Genetics, mutations, expression, and perspective for long-term inhibition.Semantic proximity Read ↗

Adenoviral-mediated expression of Pcsk9 in mice results in a low-density lipoprotein receptor knockout phenotype.Semantic proximity Read ↗

[PCSK9: Structure and function. PCSK9 and low-density lipoprotein receptor. Mutations and their effects].Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.